HomeTagsNS Pharma

NS Pharma

NS Pharma’s Brogidirsen Shows 5-Year Clinical Data in DMD Patients Amenable to Exon 44 Skipping

Popular

Frequently Asked Questions About Elevidys Used for DMD

Can Ekinci - August 21, 2026

Must Read

Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen, an Exon 51 Skipping Therapy for Duchenne Muscular Dystrophy (DMD)

Santhera Expands Biomedica Agreement to Extend AGAMREE (Vamorolone) Distribution Across Central Asia and the Caucasus

Creatine Kinase Level in Duchenne Muscular Dystrophy: Normal Ranges, High CK Levels, Diagnosis, Blood Tests & FAQs

About us

Together, we will keep fighting for better treatments and access for everyone with Duchenne.

Powered by Hostinger

Latest Articles

NS Pharma’s Brogidirsen Shows 5-Year Clinical Data in DMD Patients Amenable to Exon 44 Skipping

Press Releases October 1, 2026 0

NS Pharma’s brogidirsen (NS-089/NCNP-02) is an investigational therapy for...

ELEVIDYS WMS 2026 Data: What They Show—and What They Don’t

Press Releases October 1, 2026 0

Sarepta Therapeutics has presented new data on ELEVIDYS (delandistrogene...

Satellos Completes Enrollment in Phase 2 Forazapadin Trial for Duchenne Muscular Dystrophy

Press Releases September 30, 2026 0

Satellos Bioscience has announced the completion of enrollment in...

Most Popular

Frequently Asked Questions About Elevidys Used for DMD

Approved Therapies August 21, 2026 0

Duchenne muscular dystrophy (DMD) is a genetic condition that...

Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy

Editorials April 10, 2026 0

The landscape of potential new gene therapies for Duchenne...

The Brutal Truth: Why Duchenne Muscular Dystrophy Treatment Costs Are Out of Control

Editorials April 6, 2026 0

The duchenne muscular dystrophy treatment cost has become one...

© 2024 - 2026 DMD Warrior. All rights reserved.